Cosilon, spray 5% 60 ml

Pharmaceutical group: Dermatotropic agents.

Pharmaceutical action:

In external application of minoxidil its stimulating effect on hair growth in persons with androgenic alopecia (hair thinning, alopecia) has been noted. It improves microcirculation, stimulates the transition of hair cells into an active growing phase, changes the effect of androgens on the hair follicles. It reduces the formation of 5-alpha-dehydrotestosterone (probably indirectly), which plays a significant role in the formation of baldness.

The best effect is achieved if the follicle is not more than 10 years old, the patient is young, the baldness in the vertex is not more than 10 cm, the central baldness has more than 100 down and terminal hairs.
The appearance of hair growth is observed after 4 or more months of application of the preparation. The onset and the degree of the effect may vary from patient to patient.

After discontinuation of the use of Cosilon® the growth of new hair is suspended; within 3-4 months it is possible to restore the initial appearance. The exact mechanism of action of Cosilon® in the treatment of androgenetic alopecia is unknown. Minoxidil is ineffective in cases of alopecia caused by taking the drug, improper nutrition (iron (Fe) deficiency, vitamin A deficiency), as a result of hair styling in “tight” hairstyles.

Pharmacokinetics:

When applied externally, minoxidil is poorly absorbed through normal intact skin: on average, 1.5% (0.3-4.5%) of the total dose applied enters the systemic bloodstream. The effect of concomitant skin diseases on the absorption of minoxidil is unknown.
After discontinuation of the drug approximately 95% of minoxidil that entered the systemic bloodstream is eliminated within 4 days. The metabolic biotransformation profile of minoxidil after external use of Cosilon® has not yet been fully understood.

Minoxidil does not bind to plasma proteins and is excreted by the kidneys via glomerular filtration. Minoxidil does not penetrate the blood-brain barrier.

It is excreted mainly with the urine. Minoxidil and its metabolites are excreted by hemodialysis.

Indications

Androgenetic alopecia in men and women (with the aim of restoring hair growth or stabilizing the process of hair loss).

Pharmacological effect

Pharmaceutical group: Dermatotropic agents.

Pharmaceutical action:

When applied externally, minoxidil has been noted to have a stimulating effect on hair growth in individuals with androgenetic alopecia (hair thinning, baldness). Improves microcirculation, stimulates the transition of hair cells into the active growing phase, changes the effect of androgens on hair follicles. Reduces the formation of 5-alpha-dehydrotestosterone (possibly indirectly), which plays a significant role in the formation of baldness.

The best effect is achieved when the disease is short-lived (no more than 10 years), patients are young, the bald spot in the crown area is no more than 10 cm, and there are more than 100 vellus and terminal hairs in the center of the bald spot.
The appearance of signs of hair growth is observed after 4 or more months of using the drug. The onset and severity of the effect may vary from patient to patient.

After stopping the use of the drug Cosilon®, the growth of new hair stops; within 3-4 months, the original appearance can be restored. The exact mechanism of action of Cosilon® in the treatment of androgenetic alopecia is unknown. Minoxidil is not effective in cases of baldness caused by taking the drug, poor diet (deficiency of iron (Fe), vitamin A), as a result of styling hair in “tight” hairstyles.

Pharmacokinetics:

When applied topically, minoxidil is poorly absorbed through normal intact skin: on average, 1.5% (0.3-4.5%) of the total applied dose enters the systemic circulation. The effect of concomitant skin diseases on the absorption of minoxidil is unknown.
After stopping use of the drug, approximately 95% of minoxidil that enters the systemic circulation is eliminated within 4 days. The profile of the metabolic biotransformation of minoxidil after external use of the drug Cosilon® has not yet been fully studied.

Minoxidil does not bind to plasma proteins and is excreted by the kidneys through glomerular filtration. Minoxidil does not penetrate the blood-brain barrier.

Excreted mainly in urine. Minoxidil and its metabolites are eliminated by hemodialysis.

Special instructions

Cosilon® is applied only to dry scalp after bathing or at least 4 hours before bathing. After applying the drug to the scalp, hands should be washed thoroughly.

When using Cosilon®, it is recommended to wash your hair as usual. Hairspray and other hair care products can be used while using Cosilon®. Before applying hair care products, you must first apply Cosilon® and wait until the treated area of ​​skin is completely dry.

There is no evidence that hair coloring, perming or using hair softeners can in any way reduce the effectiveness of the drug. However, to prevent possible irritation to the scalp, you must ensure that the product is completely rinsed from the hair and scalp before using these chemicals.

Before starting treatment with Cosilon®, patients should undergo a general examination, including the collection and study of a medical history. The doctor must make sure that the scalp is healthy.

If systemic side effects or severe skin reactions occur, patients should discontinue the drug and consult a doctor.

The composition of the drug Kosilon® includes ethyl alcohol. If the drug gets on sensitive surfaces (eyes, irritated skin, mucous membranes), it is necessary to rinse the area with plenty of cold water.

Impact on the ability to drive vehicles and operate machines:

The effect of the drug on psychomotor functions was not noted. The drug does not affect the ability to drive.

Active ingredient

Minoxidil

Composition

1 ml of solution contains:

Active ingredient: minoxidil 50.00 mg;

Excipients: propylene glycol – 700.00 mg, ethanol 96% – 200.00 mg, water up to 1.00 ml.

Contraindications

Hypersensitivity, pregnancy, breastfeeding; violation of the integrity of the skin, dermatosis of the scalp.

Side Effects

From the skin: hypertrichosis, thinning and increased pigmentation of body hair; when applied topically – dryness and flaking of the scalp, dermatitis (itching, rash), eczema, increased alopecia, burning sensation of the scalp, folliculitis (sensitivity or pain at the hair roots), erythema.

Allergic reactions: rash, facial swelling, rhinitis, urticaria.

Other: sodium and water retention in the body, edema, shortness of breath, syncope, decreased libido.

Interaction

There is a theoretical possibility of increased orthostatic hypotension in patients receiving concomitant treatment with peripheral vasodilators, which, however, has not received clinical confirmation.

A very slight increased level of minoxidil in the blood of patients suffering from arterial hypertension and taking minoxidil orally cannot be excluded in case of simultaneous use of the drug Cosilon®, although corresponding clinical studies have not been conducted.

It has been established that minoxidil, when used externally, can interact with some other drugs for external use.

The simultaneous use of minoxidil solution for external use and a cream containing betamethasone (0.05%) leads to a decrease in the systemic absorption of minoxidil. Simultaneous application of minoxidil to the skin and topical drugs such as tretinoin and dithranol, which cause changes in the protective functions of the skin, may lead to increased absorption of minoxidil.

Overdose

Accidental ingestion of Cosilon® may cause systemic side effects due to the vasodilatory properties of minoxidil (5 ml of Cosilon® contain 250 mg of minoxidil, which is 2.5 times the maximum recommended dose for adults when taken orally for the treatment of arterial hypertension).

Signs of overdose: fluid retention, decreased blood pressure, tachycardia.

Treatment: to eliminate fluid retention, diuretics can be prescribed if necessary; for the treatment of tachycardia – beta-blockers.

To treat arterial hypotension, 0.9% sodium chloride solution should be administered intravenously. Symptomatic drugs, such as norepinephrine and epinephrine, which have excessive cardiac stimulating activity, should not be prescribed.

Short product description

A drug for the treatment of pathological hair loss (alopecia) in men and women: Stops hair loss. Stimulates new hair growth. Restores hair.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Manufacturer

Bosnalek JSC, Bosnia and Herzegovina